Braftovi (encorafenib) vs Vegzelma (bevacizumab-adcd)
Braftovi (encorafenib) vs Vegzelma (bevacizumab-adcd)
Braftovi (encorafenib) is a targeted therapy specifically designed to inhibit certain mutations of the BRAF gene in melanoma and metastatic colorectal cancer, making it suitable for patients whose tumors have these specific genetic alterations. On the other hand, Vegzelma (bevacizumab-adcd) is a biosimilar to Avastin (bevacizumab), which works by inhibiting vascular endothelial growth factor (VEGF), thereby preventing the growth of blood vessels that feed tumors, and is used in various cancer types, including colorectal, lung, brain, kidney, and cervical cancers. The choice between Braftovi and Vegzelma would largely depend on the type of cancer, its genetic profile, and the overall treatment plan determined by a healthcare professional.
Difference between Braftovi and Vegzelma
| Metric | Braftovi (encorafenib) | Vegzelma (bevacizumab-adcd) |
|---|---|---|
| Generic name | Encorafenib | Bevacizumab-adcd |
| Indications | Used in the treatment of melanoma with a BRAF V600E or V600K mutation | Used for various forms of cancer, including colorectal, lung, glioblastoma, kidney, and cervical cancers |
| Mechanism of action | BRAF inhibitor that helps to slow or stop the growth of cancer cells | Monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A) |
| Brand names | Braftovi | Vegzelma |
| Administrative route | Oral | Intravenous |
| Side effects | Fatigue, nausea, vomiting, abdominal pain, and increased risk of skin cancer | Hypertension, proteinuria, hemorrhage, arterial thromboembolism, and gastrointestinal perforation |
| Contraindications | None known beyond hypersensitivity to encorafenib | None known beyond hypersensitivity to bevacizumab or its excipients |
| Drug class | Kinase inhibitor | Monoclonal antibody |
| Manufacturer | Pfizer (acquired Array BioPharma) | Celltrion Healthcare |
Efficacy
Efficacy of Braftovi (Encorafenib) in Colorectal Cancer
Braftovi, known generically as encorafenib, is a targeted therapy approved for the treatment of colorectal cancer with a specific genetic profile. It is indicated for use in patients with metastatic colorectal cancer that contains a BRAF V600E mutation, as detected by an FDA-approved test. This mutation is present in a subset of colorectal cancer patients and leads to cancer growth. Encorafenib is a BRAF inhibitor that works by specifically targeting and inhibiting the activity of the mutated BRAF protein, thereby slowing down or stopping the growth of the cancer.
The efficacy of Braftovi in colorectal cancer was demonstrated in a clinical trial known as the BEACON CRC study. This trial showed that patients with BRAF V600E mutation-positive metastatic colorectal cancer who received a combination of encorafenib, binimetinib (a MEK inhibitor), and cetuximab (an EGFR inhibitor) had a significant improvement in overall survival compared to the standard of care. The trial also reported improvements in progression-free survival and response rate, indicating that this combination therapy can effectively shrink tumors and delay disease progression.
Efficacy of Vegzelma (Bevacizumab-adcd) in Colorectal Cancer
Vegzelma, also known as bevacizumab-adcd, is a biosimilar to the original bevacizumab (Avastin) product. It is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), a protein that promotes the growth of blood vessels that supply nutrients to cancerous tissues. By blocking VEGF, Vegzelma helps to starve the tumor of the nutrients it needs to grow and spread. It is used in combination with other chemotherapy treatments for metastatic colorectal cancer, among other types of cancer.
The efficacy of bevacizumab in colorectal cancer has been well established through numerous clinical trials, and Vegzelma, as a biosimilar, is designed to have no clinically meaningful differences in terms of safety, purity, and potency. Clinical studies conducted to support the approval of Vegzelma have demonstrated that it is highly similar to the reference product bevacizumab, with no significant differences in efficacy, safety, or immunogenicity in patients with advanced or metastatic cancers, including colorectal cancer. Thus, Vegzelma is considered an effective treatment option for patients with this disease, offering a similar benefit to the original bevacizumab product.
Regulatory Agency Approvals
Braftovi
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Vegzelma
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Braftovi or Vegzelma today
If Braftovi or Vegzelma are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us